News

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that ...
Ozempic, Wegovy could reverse severe liver disease, study suggests
The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...